Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol With Fixed-Dose Pembrolizumab in Unresectable Stage III and Stage IV Melanoma
NCT03384836Phase 2Suspended
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jan 2018
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of propranolol in melanoma, sponsored by Roswell Park Comprehensive Cancer Center. Started Jan 2018; status: suspended.
02
Drugs
propranolol
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03384836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384836.